Cheapest Price Guanfacine - Revaprazan Hydrochloride CAS 178307-42-1 Assay ≥99.0% API High Purity – Ruifu

Chemical Name: Revaprazan Hydrochloride
Synonyms: Revaprazan HCL
CAS: 178307-42-1 
Potassium-competitive acid blockers(P-CAB), in the treatment of duodenal ulcer, gastric ulcer and gastritis
API High Quality, Commercial Production

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer’s requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of Revaprazan Hydrochloride (CAS: 178307-42-1) with high quality.
Revaprazan Hydrochloride is the hydrochloride salt form of a lipophilic, weak base with potassium-competitive acid blocking (P-CAB) activity. Revaprazan hydrochloride reduces COX-2 expression and has significant anti-inflammatory actions activities in H. pylori infection. Revaprazan Hydrochloride in the treatment of duodenal ulcer, gastric ulcer and gastritis.
Revaprazan Hydrochloride (also known as reversible proton pump inhibitors, potassium competitive acid blockers, p-CABs) is a new generation of reversible proton pump inhibitors and the only commercially available potassium competitive acid pump inhibitors or acid pump antagonists in the world. Developed by South Korean company Yuhan and with proprietary intellectual property rights, GLAxoSmithKline has obtained worldwide development and marketing licenses for the drug outside of South Korea and North Korea. The drug was approved by the South Korean FDA in 2007 to treat duodenal ulcers and gastritis. A phase iii clinical study has been completed for the indication of gastric ulcer treatment.Indications for treatment of gastroesophageal reflux disease, functional dyspepsia and eradication of Hp have entered phase ii clinical studies. In the UK, the drug is being developed by GlaxoSmithKline and is in phase I clinical trials for the indication of gerD.
Potassium competitive acid blockers (P-CAB) O is a reversible K+ antagonist, which is different from traditional PPI. P-CAB acts by competitive inhibition of K+ in proton pumps (H+, K+ -ATPase). Since the acid inhibition effect of this drug has nothing to do with proton pump activation, it can obviously reduce the occurrence of acid breakthrough at night clinically. P-cabs are lipophilic, weakly alkaline, high dissociation constant and stable at low pH. In acidic environment, p-CABs can be ionized immediately, and H+ and K+ -ATPase can be inhibited by ionic binding in the form of ion, which can rapidly increase the pH value in the stomach without the need to concentrate on the microcapsules and microtubules of gastric wall cells and acid activation, and the enzyme activity can be recovered after dissociation. Oral absorption is rapid in both humans and animals, reaching peak plasma concentrations. Clinical and animal studies have shown that P-CABs work faster than PPI or H2 receptor blockers and increase pH more strongly. Revaprazan is more than 100 times more selective for H+ and K+ -ATPase than for Na+ and K+ -ATPASE. The results showed that p-CABs had little effect on other enzymes and physiological functions at the treatment dose.